FOLFIRINOX around surgery for resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 to 80 years old
- Have pancreatic duct adenocarcinoma confirmed by biopsy or fluid sample testing
- Your scans must show cancer that can be removed (resectable) with no distant spread
- You must be healthy enough for chemo and surgery, including blood counts, liver, and kidney tests meeting required limits
- You must not have had prior pancreatic surgery or prior chemotherapy/radiation for pancreatic cancer
- If you could become pregnant (or have a partner who could), you must use effective birth control and have a negative pregnancy test before treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
This study follows people with pancreatic cancer who are receiving a chemotherapy combination called FOLFIRINOX after surgery. The goal is to see how well the treatment works over time and how it affects long-term survival and cancer recurrence.
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
This trial tests 6 cycles of a chemotherapy combination called modified FOLFIRINOX before surgery for pancreatic cancer that can potentially be removed. The goal is to see if this approach improves outcomes for patients who might be candidates for another study called PANACHE02.
Hear when a new Neoadjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.